congress
presentations
American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting
Phoenix, Arizona
December 8-11, 2024
AXS-05 | Major Depressive Disorder
AXS-05 in Major Depressive Disorder: Pooled Data From Two Six-Week Controlled Trials (GEMINI and ASCEND)
AXS-05 | Major Depressive Disorder
Dr. Craig Chepke, MD, DFAPA describes the “AXS-05 in Major Depressive Disorder: Pooled Data from Two Six-Week Controlled Trials (GEMINI and ASCEND)” poster
AXS-05 | Major Depressive Disorder
Meaningful Patient-Reported Outcome Improvements at Weeks 1, 2, and 6 with AXS-05 for Major Depressive Disorder: Responder Analysis of the GEMINI Trial
AXS-05 | Major Depressive Disorder
Dr. Roger McIntyre MD, FRCPC describes the “Meaningful Patient-Reported Outcome Improvements at Weeks 1, 2, and 6 with AXS-05 for Major Depressive Disorder: Responder Analysis of the GEMINI Trial” poster
AXS-05 | Alzheimer’s Disease Agitation
Clinical Profile of AXS-05 in Treating Alzheimer’s Disease-Related Agitation: Results from the Phase 2/3 Development Program
AXS-05 | Alzheimer’s Disease Agitation